Business
HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders
Allowed Methods of Use Claims Directed to Administering HCW9218 to Treat Cancer, Including Killing or Reducing the Number of Senescent Cells in Subjects with
About this update from Hcw Biologics Inc.
[{"type":"text","content":"Allowed Methods of Use Claims Directed to Administering HCW9218 to Treat Cancer, Including Killing or Reducing the Number of Senescent Cells in Subjects with Cancer\nMIRAMAR, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCW Biologics” or the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, was granted U.S. Patent No. 11,672,826 on June 13, 2023, which contains methods of use claims directed to administering the Company’s clinical-stage bifunctional immunotherapeutic, HCW9218, to treat cancer, including colorectal cancer, breast cancer, ovarian cancer, hepatocellular carcinoma, gastric cancer, urothelial carcinoma, and melanoma. The patent also includes methods of use claims for killing or reducing the number of senescent cells by administering HCW9218 in subjects with cancer. Senescence is considered a physiologic process that is important in promoting wound healing, regeneration, and many other vital functions. However, stressors cause accumulation of senescent cells which modifies the microenvironment in tissues and organs and creates chronic, sterile inflammation, which drives aging and age-related diseases. This patent further strengthens the Company’s position as a leader in the emerging field of inflammaging. Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, “This patent supports our commitment to treat diseases driven by chronic inflammation typical of aging and age-related diseases, including cancer. These diseases are promoted by cellular senescence and the proinflammatory factors they secrete, known as SASP factors.” He continued, “We believe that HCW9218 has the potential to redefine the approach for treating aging conditions and age-related diseases by alleviating senescence with an immunotherapeutic therapy that rejuvenates the immune system. Aged immune systems can often breakdown and stop operating the way they were intended, and this opens the door to many age-related pathologies.” In addition to U.S. Patent No. 11,672,826, on March 26, 2023, the Company published a pivotal scientific paper in Aging Cell entitled, “Immunotherapeutic approach to reduce senescent cells and alleviate senescence-associ...